SuperGen to Highlight Oncology Pipeline Data in Multiple Presentations at the AACR-NCI-EORTC International Conference

DUBLIN, Calif., October 17, 2007 /PRNewswire-FirstCall/ -- SuperGen Inc. , a pharmaceutical company dedicated to the discovery, rapid development and commercialization of therapies for solid tumors and hematological malignancies, today announced that multiple abstracts have been accepted for poster presentations at the AACR-NCI-EORTC International Conference from Oct. 22-26 at the Moscone Center in San Francisco.

The poster presentations will focus on data concerning many of SuperGen's current oncology programs including the lead clinical compound, MP470, and its ability to suppress the repair of double stranded DNA breaks following treatment with DNA-damaging agents.

In addition to the poster presentations listed below, data on SuperGen's hypomethylating agent, S110, will be presented by Dr. Peter A. Jones on Wednesday, Oct. 24 at 8:00 a.m. in Plenary Session 3: Epigenetic Targets.

    SuperGen's schedule of presentations is as follows:


                                                             Poster

    Date       Time (PDT)        Abstract # and Title    Number/Session


    Tuesday,   12:30 p.m.-       # 1026 - MP470          #A173

    Oct. 23    2:30  p.m.        suppresses repair of

                                 double-strand breaks    Poster Session A

               5:30 p.m.-        following treatment

               7:30 p.m.         with DNA-damaging

                                 agents


    Wednesday, 12:30 p.m.-       # 1038 - The            #B140

    Oct. 24    2:30  p.m.        decitabine-derived

                                 demethylating           Poster Session B

               5:30 p.m.-        dinucleotide, S110

               7:30 p.m.         shows improved

                                 activity due to

                                 increased drug

                                 delivery and

                                 stability


    Thursday,  12:30 p.m.-       # 907 - Effect of       #C200

    Oct. 25    2:30  p.m.        small molecule

                                 inhibitors of JAK2      Poster Session C

               5:30 p.m.-        kinase on modulating

               7:30 p.m.         signaling cascades

                                 downstream of

                                 cytokine receptors


    Thursday,  12:30 p.m.-       # 985 - A small         #C208

    Oct. 25    2:30  p.m.        molecule inhibitor of

                                 Pim-1 kinase with       Poster Session C

               5:30 p.m.-        activity in both

               7:30 p.m.         hematological and

                                 solid tumor

                                 malignancies

About SuperGen

Based in Dublin, Calif., SuperGen, Inc. is a pharmaceutical company dedicated to the discovery, rapid development and commercialization of therapies for solid tumors and hematological malignancies. SuperGen is developing a number of therapeutic anticancer products focused on kinase and cell signaling inhibitors and DNA methyltransferase inhibitors. For more information about SuperGen, please visit http://www.supergen.com.

Forward-Looking Statements

This news release contains certain "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are typically preceded by words such as "believes," "expects," "anticipates," "intends," "will," "may," "should," or similar expressions. These forward-looking statements are not guarantees of future performance and involve a number of risks and uncertainties that may cause actual results to differ materially from the results discussed in these statements. Factors that might cause the company's results to differ materially from those expressed or implied by such forward-looking statements include, but are not limited to, the ability to discover, develop and move target compounds into clinical development and other risks and uncertainties detailed from time to time in the company's filings with the Securities and Exchange Commission including its most recently filed Form 10-Q and 10-K. SuperGen, Inc. undertakes no duty to update any of these forward-looking statements to conform them to actual results.

    Contacts

    Timothy L. Enns                           Mary M. Vegh

    SuperGen, Inc.                            SuperGen, Inc.

    SVP, Corporate Communications             Manager, Investor Relations

    & Business Development                    Tel: (925) 560-2845

    Tel: (925) 560-0100                       E-mail: 

    E-mail: 

mary.vegh@supergen.com tenns@supergen.com

CONTACT: Timothy L. Enns, SVP, Corporate Communications & BusinessDevelopment, +1-925-560-0100, , or Mary M. Vegh, Manager,Investor Relations, +1-925-560-2845, , both ofSuperGen, Inc. tenns@supergen.com mary.vegh@supergen.com

Web site: http://www.supergen.com/

Ticker Symbol: (NASDAQ-NMS:SUPG)

Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights reserved.
A United Business Media Company

Posted: October 2007

View comments

Hide
(web3)